This is called prehabilitation or prehab. After treatment you usually have follow up appointments to check how you are and see whether you have any problems or worries. Ovarian cancer can come back ...

This means there is an opportunity to develop alternate, potentially more effective, treatments for ovarian cancer within the current landscape. Ovarian cancer treatment hinges on disease stage ...

Ovarian cancer ... markers of ovarian cancer. Doctor Debernardo and his team are also part of the first international trial of its kind, using CAR t-cell therapy for treatment.

You normally have about 6 cycles in all, but you may have more. It takes 3 to 4 hours to have each treatment in the outpatients department. On rare occasions you might have it over 24 hours, when you ...

An MRI-based imaging technique predicts the response of ovarian cancer tumors to treatment, and rapidly reveals how well treatment is working, in patient-derived cell models. An MRI-based imaging ...

As the first FRα-targeted ADC approved in the EU, Elahere represents a competitive advantage for AbbVie in the ovarian cancer treatment landscape. GlobalData is the parent company of ...

When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...

Different forms of ovarian cancer respond differently to drug treatments. With current tests, patients typically wait for weeks or months to find out whether their cancer is responding to treatment.

(RTTNews) - Biopharmaceutical company Verastem Oncology (VSTM) Monday said that its treatment for a rare form of ovarian cancer has been given priority review by the Food and Drug Administration.